위원회 위원명단 - 대한내과학회

coronary atherosclerosis. A randomized controlled trial. JAMA 2004;291:1071-80.
12. LaRosa JC, Grundy SM, Waters DD, et al. For the Treating to New Targets (TNT)
Investigators. Intensive Lipid Lowering with Atorvastastin in patients with Stable
Coronary Disease. N Engl J Med 2005;352:1425-35.
13. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and
ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study [published
erratum appears in Circulation 1998 May 19;97:1995]. Circulation 1998;97:
1029-36.
14. Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension,
dyslipidemia, and coronary heart disease. Am Heart J 1991;121:1283-8.
15. Vega GL, Grundy SM. Management of primary mixed hyperlipidemia with lovastatin.
Arch Intern Med 1990;150:1313-9.
16. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for
the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
J Am Coll Cardiol 2004;44(3):720-32.
17. Tompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention
and treatment of atherosclerotic cardiovascular disease. Circulation 2003;
107:3109.
18. The Diabetes Control and Complications Trial Research Group. The effect of intensive
treatment of diabetes on the development and progression of long-term
complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:
977-86.
19. Getz GS. Report on the workshop on diabetes and mechanisms of atherogenesis.
September 17th and 18th, 1992, Bethesda, Maryland. Arterioscler Thromb 1993;13:
459-64.
20. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Rozek MM. Pathogenesis
of the atherosclerotic lesion. Implications for diabetes mellitus. Circulation
1992;15:1156-67.
21. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double-blind
trial of aspirin in primary prevention of myocardial infarction in patients
with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial
(SAPAT) Group. Lancet 1992;340:1421-5.
22. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial
infarction. N Engl J Med 2002;347:969-74.
23. Yusur S, Sleight P, Pogue J, Bosch J, et al. Heart Outcomes Prevention Evaluation
(HOPE) study investigators. Effects of ramipril on cardiovascular and microvascular
outcomes in people with diabetes mellitus: results of the HOPE study and
MICRO_HOPE substudy. Lancet 2000;255:253.
24. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan in patients
with chronic heart failure and preserved left-ventricular ejection fraction: the
CHARM-Preserved Trial. Lancet 2003;362:777-81.
25. Yusuf S et al. Telmisartan, ramipril, or both in patients at high risk for vascular
events. New England Journal of Medicine, The, 2008;358(15):1547-59.
붉은색 부분 확인바랍니다
26. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, Bresee JS,
Cox NS. Prevention and Control of Influenza: Recommendations of the Advisory
Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008;
안정형 협심증의 개정판
121